Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer (NCT07036978) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer
Taiwan140 participantsStarted 2026-05-01
Plain-language summary
Brief Summary
The goal of this observational study is to identify biomarkers and develop a personalised treatment stratification model for patients with unresectable pancreatic ductal adenocarcinoma (PDAC) in Taiwan. The main questions it aims to answer are:
* What serum metabolomic profiles predict treatment response and patient survival?
* How do immune response markers and gut microbiome composition correlate with therapeutic outcomes?
* Can a combined multi-omic stratification algorithm enhance personalised therapy planning?
Participants, who have been diagnosed with unresectable locally advanced or metastatic PDAC and are undergoing systemic therapy and chemoradiotherapy, will:
* Provide serum samples for comprehensive metabolomic profiling via high-performance liquid chromatography-mass spectrometry.
* Undergo immune profiling through flow cytometry.
* Provide stool samples for gut microbiome analysis using 16S rRNA sequencing.
* Be followed longitudinally to correlate these multi-omic findings with clinical outcomes.
Researchers anticipate that integrating these multi-omic analyses will facilitate personalised therapy approaches, potentially improving patient outcomes.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Unresectable disease status determined by a multidisciplinary tumour board (either locally advanced disease encasing critical vessels or distant metastases present).
ā. Planned initiation of systemic therapy (first-line chemotherapy or chemo + experimental immunotherapy trial) as part of standard care - this ensures a uniform starting point for outcome measurement.
ā. Adequate organ function to undergo therapy (renal, hepatic, bone marrow parameters within acceptable range) and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, indicating patients well enough to participate and undergo required blood draws and sample collection.
ā. Ability to provide informed consent, with no severe comorbid conditions that would preclude study procedures (e.g. unable to provide stool sample or undergo blood draws).
Exclusion criteria
ā. Prior systemic therapy for metastatic PDAC.
ā. Current use of long-term antibiotics or probiotics that could significantly alter the gut microbiome unless they are willing to pause these interventions (to avoid confounding in microbiome analysis).
ā
What they're measuring
1
Treatment response classification based on metabolomic profiles
Timeframe: At baseline (prior to treatment initiation) and at first radiographic evaluation (8-12 weeks after treatment initiation).